PMP22 and Charcot-Marie-Tooth disease type 1A: After validating AAV9-miR871 in vivo PNS biodistribution and PMP22 and Pmp22 gene silencing efficacy, we proceeded with a proof-of-concept treatment trial at early stages of neuropathy in the CMT1A mouse model.